



Stellate Therapeutics Expands NYC Scientific Team and Opens Research Laboratory

***YoneJung Yoon joins as Research Scientist and
Laboratory Operations Commence in Soho***

Paris, France – 26th October 2021: Stellate Therapeutics Inc. (“the Company”, “Stellate”), a global biotechnology company developing disease-modifying therapies for neurological conditions based on molecules derived from the microbiome, announces the expansion of the Company’s New York City-based scientific team and the opening of its research laboratory in JLABS @ NYC, Johnson & Johnson Innovation’s premier life science incubator program.

This follows the publication of Stellate’s first peer-reviewed publication in [PloS One](#) earlier this month that showed positive neuroprotective results for Stellate’s lead drug candidate, STL-101, in neuronal cell models of proteinopathies and neurodegeneration such as Parkinson’s and Alzheimer’s diseases. Progressing the STL-101 research program, the addition of a new hire combined with the ability to perform critical in-house experiments through our new laboratory will support the Company in advancing STL-101 towards clinical trials in 2022.

With over a decade of experience in cellular, molecular and neurobiology, **YoneJung Yoon, PhD**, joins as a Research Scientist and will be responsible for establishing many of the Alzheimer’s disease *in-vitro* models, protocols and experiments that will further our understanding of the mechanism of action for STL-101. Prior to joining Stellate, Dr. Yoon worked at Icahn School of Medicine at Mt. Sinai and earned her degrees from The University of Vermont and Yonsei University.

Sophie Durand, Chief Executive Officer of Stellate Therapeutics, said: “I am delighted to be welcoming YoneJung Yoon to Stellate Therapeutics. With her strong expertise and background, she will help Stellate accelerate its path towards clinical trials through the work in our new US-based research laboratory.”

About Stellate Therapeutics

Stellate Therapeutics is a private global biotechnology company that develops small molecules produced by the microbiome into first-in-class therapies for neurological diseases (Parkinson and Alzheimer diseases). Stellate is also evaluating a portfolio of new drug candidates in other conditions, with capabilities across discovery, screening, production and diagnostic development. Stellate Therapeutics is a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program. For more information, visit www.stellate-tx.com.

Contact

Stellate Therapeutics

Sophie Durand, Chief Executive Officer
s.durand@stellate-tx.com

Consilium Strategic Communications

Amber Fennell, Carina Jurs, Genevieve Wilson
+44 (0) 203 709 5000
eurekare@consilium-comms.com